Condition: Adult · Middle Aged · Elective Surgical Procedures · Sponsor: Korea University Guro Hospital
Remimazolam is primarily metabolized via CES1, and other drugs that are commonly metabolized by CES1 are known to have their pharmacokinetics and clinical effects affected by genetic polymorphisms in CES1. The goal of this observational study is to investigate the impact of the CES1 genotype on the pharmacokinetics, safety, and efficacy of remimazolam in patients undergoing elective surgery.
This description comes directly from the study's public registry record.
Byung Gun Lim, MD, PhD · 82-2-2626-1437 · bglim9205@korea.ac.kr
Hye Bin Kim, MD, PhD · 82-10-9183-5617 · aneshbkim@gmail.com
Always discuss trial participation with your own doctor first.
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05841667